Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK2 | Q9HBH9 | 18/20 | 1.00 |
| ▸ | MKNK1 | Q9BUB5 | 13/20 | 0.74 |
| ▸ | EIF4E | P06730 | 1/20 | 0.57 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.57 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17362685 | 0.85 | MKNK2 (1.00) | MKNK2MKNK1EIF4ECLK4STK17A | |
| SCHEMBL17362655 | 0.84 | MKNK2 (1.00) | MKNK2MKNK1 | |
| SCHEMBL17362579 | 0.84 | MKNK2 (0.80) | MKNK2MKNK1EIF4ECLK4STK17A | |
| SCHEMBL17362890 | 0.84 | MKNK2 (1.00) | MKNK2MKNK1EIF4ECLK4STK17A | |
| Hydrochloric Acid SCHEMBL17362918 | 0.84 | MKNK2 (0.98) | MKNK2MKNK1 | |
| SCHEMBL17363011 | 0.83 | MKNK2 (0.98) | MKNK2MKNK1 | |
| SCHEMBL18863103 | 0.82 | MKNK1 (1.00) | MKNK2MKNK1 | |
| SCHEMBL18863088 | 0.82 | MKNK2 (0.74) | MKNK2MKNK1 | |
| SCHEMBL18863089 | 0.81 | MKNK1 (0.70) | MKNK2MKNK1 | |
| SCHEMBL17362516 | 0.81 | MKNK2 (0.72) | MKNK2MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000487-B2 | Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers | EFFECTOR THERAPEUTICS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-10000487-B2 | Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers | EFFECTOR THERAPEUTICS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-10000487-B2 | Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers | EFFECTOR THERAPEUTICS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170145009-A1 | HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS | EFFECTOR THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170145009-A1 | HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS | EFFECTOR THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170145009-A1 | HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS | EFFECTOR THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000487-B2 | Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers | MAP3K9, MAP3K19, MAP3K20 | MKNK2 62/4885MKNK1 78/4885EIF4E 772/4885 |
| US-20170145009-A1 | HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS | MAP3K9, MAP3K19, MAP3K20 | MKNK2 62/4885MKNK1 78/4885EIF4E 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.